Role of intratumoral infiltrating macrophages after transarterial immunoembolization for hepatocellular carcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 23, Issue 5, 2016, Pages 298-304

  Kenjo, Akira ^a   Sato, Tetsu ^a   Marubashi, Shigeru ^a   Saito, Takuro ^a   Tsuchiya, Takao ^a   Kimura, Takashi ^a   Sato, Naoya ^a   Takahashi, Atsushi ^a   Ohira, Hiromasa ^a   Gotoh, Mitsukazu ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Immune response; Macrophage; OK 432

Indexed keywords

CD68 ANTIGEN; CD8 ANTIGEN; PICIBANIL; ANTINEOPLASTIC AGENT; CD163 ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LIVER CELL CARCINOMA; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; OUTCOME ASSESSMENT; RECURRENCE FREE SURVIVAL; TRANSARTERIAL IMMUNOEMBOLIZATION; TUMOR NECROSIS; TUMOR RECURRENCE; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CHEMOEMBOLIZATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MACROPHAGES; MALE; MIDDLE AGED; PICIBANIL; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84962683484     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.342     Document Type: Article

References (32)

1. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-17.
2. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al., Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243: 229-35.
3. Kanai T, Monden M, Sakon M, Gotoh M, Umeshita K, Hasuike Y, et al., New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother Pharmacol. 1994; 33 Suppl: S48-54.
4. Yoshida T, Sakon M, Umeshita K, Kanai T, Miyamoto A, Takeda T, et al., Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol. 2001; 32: 59-65.
5. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A,. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23: 549-55.
6. Sica A, Mantovani A,. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122: 787-95.
7. Saito T, Tsuchiya T, Sato Y, Kenjo A, Kimura T, Anazawa T, et al., Effect of Transarterial Immunoembolization as Preoperative Treatment for Hepatocellular Carcinoma. Ann Cancer Res Therap. 2011; 19: 26-33.
8. Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, et al., Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer. 1992; 69: 913-9.
9. JSH. Clinical Practice Guidelines for Hepatocellular Carcinoma, 3rd edn. Tokyo, Japan: Kanehara Shuppan; 2013. p. 87-8.
10. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al., The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013; 2013: 187204.
11. Higuchi T, Kikuchi M, Okazaki M,. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994; 73: 2259-67.
12. Hsu HC, Wei TC, Tsang YM, Wu MZ, Lin YH, Chuang SM,. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer. 1986; 57: 1184-91.
13. Chambers TJ,. Multinucleate giant cells. J Pathol. 1978; 126: 125-48.
14. Takushi Monden HM, Shimano T, Yagyu T, Murotani M, Nagaoka H, Kawasaki Y, et al., Use of Fibrinogen to Enhance the Antitumor Effect of OK-432. A New Approach to Immunotherapy for Colorectal Carcinoma. Cancer. 1992; 69: 636-42.
15. Tsutomu Takeda TK, Monden T, Katsumoto Y, Ito Y, Wakasugi E, Wakasugi T, et al., The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages. Biotherapy. 1993; 7: 47-54.
16. Sekimoto M, Kokunai I, Shimano T, Kobayashi T, Takeda T, Haruna N, et al., Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432 in vitro, and its augmentation by human interferon gamma. J Clin Lab Immunol. 1988; 27: 115-20.
17. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M,. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998; 27: 407-14.
18. Ohno S, Tachibana M, Fujii T, Ueda S, Kubota H, Nagasue N,. Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int J Cancer. 2002; 97: 770-4.
19. Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, et al., Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients-a study of the OVCAD consortium. BMC Cancer. 2013; 13: 422.
20. Hanahan D, Coussens LM,. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21: 309-22.
21. Joyce JA, Pollard JW,. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9: 239-52.
22. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature. 2008; 454: 436-44.
23. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-45.
24. Bingle L, Brown NJ, Lewis CE,. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196: 254-65.
25. Lewis CE, Pollard JW,. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66: 605-12.
26. Solinas G, Germano G, Mantovani A, Allavena P,. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009; 86: 1065-73.
27. Falini B, Flenghi L, Pileri S, Gambacorta M, Bigerna B, Durkop H, et al., PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol. 1993; 142: 1359-72.
28. Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M,. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004; 24: 3295-301.
29. Sako M, Hirota S, Hasegawa M, Shimizu T, Hase M, Tanaka K, et al., Transchatheter Hepatic Arterial Embolization with Embolic Materials Containing OK-432. J Jpn Soc Cancer Ther. 1987; 22: 12.
30. Okamoto H, Shoin S, Koshimura S, Shimizu R,. Studies on the Anticancer and Streptolysin S-Forming Abilities of Hemolytic Streptococci. Jpn J Microbiol. 1967; 11: 323-36.
31. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K,. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg. 1994; 168: 36-40.
32. Smiley ST, King JA, Hancock WW,. Fibrinogen Stimulates Macrophage Chemokine Secretion Through Toll-Like Receptor 4. J Immunol. 2001; 167: 2887-94.